ClinVar Miner

Submissions for variant NM_000492.4(CFTR):c.328G>T (p.Asp110Tyr)

dbSNP: rs113993958
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000508454 SCV000603068 likely pathogenic not specified 2017-03-15 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001705706 SCV001370734 pathogenic Cystic fibrosis 2024-01-16 criteria provided, single submitter clinical testing Variant summary: CFTR c.328G>T (p.Asp110Tyr) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251100 control chromosomes. c.328G>T has been reported in the literature in compound heterozygous individuals affected with CAVD and CF, several of whom carrry F508Del as second allele (Casals_2000, Qu_2023, Bauer_2021, Raraigh_2022). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two variants at same codon have been classified as pathogenic by our lab: (p.Asp110His, p.Asp110Glu). The following publications have been ascertained in the context of this evaluation (PMID: 33512069, 10875853, 25024266, 22483971, 27157324, 16126774, 36604502, 25735457, 34782259). ClinVar contains an entry for this variant (Variation ID: 53705). Based on the evidence outlined above, the variant was classified as pathogenic.
Genome-Nilou Lab RCV001705706 SCV001821990 likely pathogenic Cystic fibrosis 2021-07-22 criteria provided, single submitter clinical testing
Invitae RCV001705706 SCV002174946 likely pathogenic Cystic fibrosis 2024-01-08 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 110 of the CFTR protein (p.Asp110Tyr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with congenital bilateral absence of the vas deferens (CBAVD) and/or cystic fibrosis (PMID: 10875853, 34782259). ClinVar contains an entry for this variant (Variation ID: 53705). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CFTR protein function with a positive predictive value of 80%. This variant disrupts the p.Asp110 amino acid residue in CFTR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9272157, 18373402, 19897426, 22724884). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Ambry Genetics RCV001705706 SCV002606041 uncertain significance Cystic fibrosis 2022-09-05 criteria provided, single submitter clinical testing The p.D110Y variant (also known as c.328G>T), located in coding exon 4 of the CFTR gene, results from a G to T substitution at nucleotide position 328. The aspartic acid at codon 110 is replaced by tyrosine, an amino acid with highly dissimilar properties. This alteration in men with congenital absence of the vas deferens (CAVD) (Casals T et al. Hum Reprod. 2000;15(7):1476-83; Feng J et al. Reproduction, 2022 Sep;164:R47-R56). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
PreventionGenetics, part of Exact Sciences RCV004537229 SCV004117849 uncertain significance CFTR-related disorder 2022-12-27 criteria provided, single submitter clinical testing The CFTR c.328G>T variant is predicted to result in the amino acid substitution p.Asp110Tyr. In the literature this variant is also reported as c.460G>T and D110Y. This variant has been reported along with the CFTR ∆F508 variant in an individual with congenital absence of the vas deferens (CAVD) (Casals et al. 2000. PubMed ID: 10875853). However, in a large study of individuals with infertility, this variant was reported in the control population (Morea et al. 2005. PubMed ID: 16126774). Functional studies have shown the p.Asp110Tyr variant leads to CFTR channel instability (Cui et al. 2014. PubMed ID: 25024266). This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD ( and is reported with conflicting interpretations regarding its pathogenicity in ClinVar, ranging from uncertain to likely pathogenic ( At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.
Mayo Clinic Laboratories, Mayo Clinic RCV003480044 SCV004226568 likely pathogenic not provided 2022-10-21 criteria provided, single submitter clinical testing PP3, PM2, PM3_supporting, PM5

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.